I'm LongbridgeAI, I can summarize articles.Revenue: As of FY2026 Q2, the actual value is USD 0.
EPS: As of FY2026 Q2, the actual value is USD -0.45, missing the estimate of USD -0.334.
EBIT: As of FY2026 Q2, the actual value is USD -32.74 M.
Cash, Cash Equivalents, and Marketable Securities
As of June 30, 2026, Acumen Pharmaceuticals, Inc. reported cash, cash equivalents, and marketable securities totaling $110.2 million, which is a decrease from $128.4 million as of March 31, 2026, and $116.865 million as of December 31, 2025.
Research and Development (R&D) Expenses
R&D expenses for the second quarter of 2026 were $27.8 million, a decrease compared to $37.1 million for the second quarter of 2025. For the six months ended June 30, 2026, R&D expenses were $44.293 million, down from $62.391 million for the same period in 2025. This reduction was primarily due to lower manufacturing, materials, and CRO costs associated with the ALTITUDE-AD clinical trial.
General and Administrative (G&A) Expenses
G&A expenses for the second quarter of 2026 were $4.7 million, slightly up from $4.6 million for the second quarter of 2025. For the six months ended June 30, 2026, G&A expenses were $9.412 million, compared to $9.729 million for the same period in 2025.
Loss from Operations
Loss from operations for the second quarter of 2026 was - $32.6 million, an improvement from - $41.8 million for the second quarter of 2025, primarily due to decreased R&D expenses. For the six months ended June 30, 2026, loss from operations was - $53.705 million, compared to - $72.120 million for the same period in 2025.
Net Loss
Acumen Pharmaceuticals, Inc. reported a net loss of - $32.7 million for the second quarter of 2026, an improvement from a net loss of - $41.0 million for the second quarter of 2025. For the six months ended June 30, 2026, the net loss was - $53.455 million, compared to - $69.746 million for the same period in 2025.
Net Cash Used in Operating Activities
Net cash used in operating activities for the six months ended June 30, 2026, was - $42.203 million, an improvement from - $65.953 million for the same period in 2025.
Balance Sheet Highlights
Total assets as of June 30, 2026, were $116.007 million, down from $122.833 million as of December 31, 2025. Total liabilities increased to $58.744 million as of June 30, 2026, from $52.403 million as of December 31, 2025. Total stockholders’ equity decreased to $57.263 million as of June 30, 2026, from $70.430 million as of December 31, 2025.
Operational Metrics and Milestones
Acumen Pharmaceuticals, Inc. completed enrollment for its 542-participant ALTITUDE-AD Phase 2 trial in Q1 2025, with the open-label extension portion starting in November 2025. Topline results for the Phase 1 subcutaneous study were announced in Q1 2025, indicating systemic exposure supports further clinical development. The company announced pre-clinical candidate data for its Enhanced Brain Delivery (EBD™) program in early 2026, and holds an exclusive option to license and develop up to two candidates under an agreement with JCR Pharmaceuticals. Sabirnetug’s composition of matter patents and methods of use are valid until July 2031, with potential extensions, and the company expects 12 years of market exclusivity in the U.S. and 10 years in Europe. The INTERCEPT-AD study showed a limited incidence of Amyloid-Related Imaging Abnormalities - Edema (ARIA-E), with approximately 10% of cases and no ARIA-E in ApoE4 homozygotes, with no study drug-related deaths or serious adverse events.
Outlook and Guidance
Acumen Pharmaceuticals, Inc. anticipates its cash, cash equivalents, and marketable securities will fund current clinical and operational activities into early 2027. The company expects to report topline results for its Phase 2 ALTITUDE-AD study in late 2026. Additionally, Acumen Pharmaceuticals, Inc. is targeting an Investigational New Drug (IND) filing for a lead clinical candidate in its Enhanced Brain Delivery™ (EBD™) program by mid-2027.